# Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)

> **NCT06084780** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Case Comprehensive Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Secondary Malignant Neoplasm of Retroperitoneum
- Secondary Malignant Neoplasm of Peritoneum
- Pseudomyxoma Peritonei

## Interventions

- **PROCEDURE:** Intestinal, Multivisceral or Modified Multivisceral Transplantation
- **DRUG:** Alemtuzumab
- **DRUG:** Tacrolimus
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT06084780
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06084780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06084780, "Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06084780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*